Geninus Inc is a Korea-based company principally engaged in the bioinformatics analysis business. The Company is engaged in the provision of single cell analysis services, genetic testing for disease prediction for the public, cancer genome analysis solutions based on tissue biopsy and other services. It is also engaged personal genetic testing, software development, rental business and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-19	₩1,690.00	+2.42%	258,050
26-10-16	₩1,650.00	+4.76%	212,388
26-10-15	₩1,575.00	-9.53%	332,810
26-10-14	₩1,741.00	+0.17%	182,793
26-10-13	₩1,738.00	-5.54%	389,979

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 2026-10-19			5-day change	1st Jan Change
1,690.00 ^KRW	+2.42%		-8.15%	-51.71%

03-24	GENINUS Inc. announced that it has received KRW 19.999993583 billion in funding from KB Investment Co., Ltd, Company K Partners Limited	CI
03-05	GENINUS Inc. announced that it expects to receive KRW 19.999993583 billion in funding from KB Investment Co., Ltd, Company K Partners Limited	CI

Market Cap	66.57B 49.99M 44.56M 41.28M 37.54M 70.43M 4.74B 71.59M 495M 195M 2.48B 188M 184M 7.92B	P/E 2024	-3.73x	P/E 2025	-6.72x
Enterprise Value	62.09B 46.62M 41.56M 38.5M 35M 65.69M 4.42B 66.77M 462M 182M 2.31B 175M 171M 7.39B	EV / Sales 2024	6.46x	EV / Sales 2025	10.7x
Free-Float	73.35%	Yield 2024 *	-	Yield 2025	-

03-24	GENINUS Inc. announced that it has received KRW 19.999993583 billion in funding from KB Investment Co., Ltd, Company K Partners Limited	CI
03-05	GENINUS Inc. announced that it expects to receive KRW 19.999993583 billion in funding from KB Investment Co., Ltd, Company K Partners Limited	CI
25-05-21	GENINUS Inc. announced that it has received KRW 10 billion in funding from AJU IB INVESTMENT Co., Ltd., Korea Investment & Securities Co., Ltd., Korea Investment Partners Co. Ltd. and other investors	CI
25-05-18	GENINUS Inc. announced that it expects to receive KRW 10 billion in funding from AJU IB INVESTMENT Co., Ltd., Korea Investment & Securities Co., Ltd., Korea Investment Partners Co. Ltd. and other investors	CI
21-11-01	GENINUS Inc. has completed an IPO in the amount of KRW 40 billion.	CI
21-07-08	GENINUS Inc. has filed an IPO.	CI

1 day	+2.42%
1 week	-8.15%
Current month	-14.82%
1 month	-13.47%
3 months	-25.71%
6 months	-69.38%
Current year	-51.71%

GENINUS Inc. Stock

Stocks

A389030

KR7389030008

Biotechnology & Medical Research

Valuation: GENINUS Inc.

Chart: GENINUS Inc.

Latest news: GENINUS Inc.

Quotes and Performance

Price Extremes

Managers and Directors: GENINUS Inc.

Latest insider transactions

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

1 week	1,555	1,789
1 month	1,555	2,500
Current year	1,555	6,480
1 year	1,555	6,480
3 years	1,080	6,480
5 years	1,080	6,483.33
10 years	1,080	6,483.33

Manager	Title	Age	Since
Woong-Yang Park CEO	Chief Executive Officer	63	2018-03-31
Kwan-Soo Kim DFI	Director of Finance/CFO	42	2025-02-28
Hae-Seong No CTO	Chief Tech/Sci/R&D Officer	44	2026-03-31

Director	Title	Age	Since
Woong-Yang Park BRD	Director/Board Member	63	2018-03-31
Jung-Kyu Han BRD	Director/Board Member	63	2021-06-29
Sang-Hyeok Lee BRD	Director/Board Member	63	2023-03-29

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
1/30/24	Sang-Hyeok Lee	Buy	Director	1,000	0.0030%
1/30/24	Sang-Hyeok Lee	Buy	Director	1,000	0.0030%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENINUS INC.	+2.42%	-8.15%	-11.33%	-51.37%	49.99M
WUXI APPTEC CO., LTD.	+1.52%	-7.19%	+51.66%	+69.99%	65.83B
LONZA GROUP AG	+0.46%	+6.83%	+10.77%	+79.30%	51.87B
ARGENX SE	+1.48%	+2.98%	+1.37%	+63.25%	51.2B
IQVIA HOLDINGS INC.	-0.38%	+1.40%	+29.98%	+42.37%	43.76B
BEONE MEDICINES AG	+0.30%	+5.64%	+16.99%	+133.30%	42.09B
REVOLUTION MEDICINES, INC.	+2.35%	-6.08%	+236.69%	+528.10%	39.04B
CELLTRION, INC.	+2.16%	+9.87%	+18.92%	+59.70%	34B
WUXI BIOLOGICS (CAYMAN) INC.	+4.15%	-2.05%	+39.60%	+8.89%	25.2B
GENMAB A/S	+1.10%	+2.21%	+21.34%	+28.00%	22.8B
Average	+1.70%	-0.03%	+41.60%	+96.15%	37.59B
Weighted average by Cap.	+1.47%	+0.20%	+46.36%	+114.22%

	2024	2025
Net sales	6.46B 4.85M 4.32M 4M 3.64M 6.83M 460M 6.94M 48.01M 18.88M 240M 18.19M 17.81M 768M	10.48B 7.87M 7.02M 6.5M 5.91M 11.09M 746M 11.27M 77.97M 30.66M 390M 29.54M 28.92M 1.25B
Net income	-12.27B -9.22M -8.22M -7.61M -6.92M -12.99M -874M -13.2M -91.29M -35.9M -457M -34.58M -33.86M -1.46B	-17.37B -13.05M -11.63M -10.77M -9.8M -18.38M -1.24B -18.68M -129M -50.81M -646M -48.95M -47.93M -2.07B
Net Debt	-4.14B -3.11M -2.77M -2.57M -2.33M -4.38M -295M -4.45M -30.8M -12.11M -154M -11.67M -11.42M -493M	-4.49B -3.37M -3M -2.78M -2.53M -4.75M -320M -4.83M -33.38M -13.13M -167M -12.64M -12.38M -534M